Peptide regulation in the United States spans drug approval pathways, pharmacy compounding lists, and research-use-only catalog commerce. This timeline helps procurement teams orient news headlines to the correct regulatory bucket. It is not legal advice.
2023
FDA continued categorizing nominated bulk drug substances for compounding under 503A. Several peptides appeared on Category 2 (not eligible for compounding) discussions in docket materials — signaling tighter pharmacy compounding boundaries distinct from RUO catalog sales.
2024
Public dockets and FDA communications referenced peptides such as BPC-157, TB-500 fragments, CJC-1295, ipamorelin, AOD-9604, thymosin alpha-1, and selank in compounding and enforcement contexts. Research catalog suppliers emphasized RUO labeling and documentation.
Early 2026
Federal policy statements and advisory committee agendas continued to frame peptide access through licensed supply chains. PCAC-related reviews for specific peptides remained active in published meeting materials — laboratories should read primary FDA sources quarterly.
Ongoing
Maintain batch COAs, align purchases with institutional policy, and separate compounding-pharmacy rules from RUO catalog procurement. Use /guides/ruo-documentation-checklist and /guides/how-to-read-peptide-coa for internal QA files.